Can-Fite BioPharma Business Summary

Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biopharmaceutical company specializing in the development of small molecule orally bioavailable drugs targeting the A3 adenosine receptor (A3AR). The company generates revenue through a business model centered on strategic out-licensing agreements, upfront payments, and milestone-based fees from global pharmaceutical partners, including regional deals in Europe, Asia, and Canada. Its primary business segments focus on inflammatory diseases, led by its flagship candidate Piclidenoson for plaque psoriasis, and oncology/liver diseases, centered on Namodenoson for hepatocellular carcinoma and MASH. Can-Fite competes in a high-stakes market against major incumbents such as Amgen (Otezla), Bristol Myers Squibb (Sotyktu), and AbbVie (Skyrizi), positioning itself as a provider of safer, small-molecule oral alternatives to traditional biologics by leveraging the over-expression of A3AR in pathological cells to minimize off-target toxicity. The company was co-founded by Dr. Pnina Fishman, who serves as Executive Chairman and Chief Scientific Officer, drawing on her extensive background in clinical oncology and molecular biology from the Rabin Medical Center. The executive leadership is headed by CEO Motti Haimi, who brings significant experience in international pharmaceutical management and commercial strategy to guide the firm through its pivotal Phase III trials. Financial operations are managed by CFO Dr. Sari Fishman, who oversees the company’s dual listing on the NYSE American and TASE. The board of directors features seasoned professionals like patent expert Dr. Ilan Cohn, and the company’s scientific pedigree is reinforced by its proprietary biomarker technology, which allows for personalized medicine applications that have historically attracted institutional investment from biotech-focused funds.